IsoPlexis (NASDAQ:ISO – Get Rating) is one of 43 public companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare IsoPlexis to similar companies based on the strength of its earnings, institutional ownership, valuation, dividends, risk, analyst recommendations and profitability.
Earnings & Valuation
This table compares IsoPlexis and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| IsoPlexis | $16.76 million | -$106.00 million | -0.28 |
| IsoPlexis Competitors | $1.07 billion | -$256.75 million | 5.02 |
IsoPlexis’ peers have higher revenue, but lower earnings than IsoPlexis. IsoPlexis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IsoPlexis | 0 | 2 | 0 | 0 | 2.00 |
| IsoPlexis Competitors | 193 | 1104 | 1712 | 59 | 2.53 |
IsoPlexis currently has a consensus target price of $1.60, suggesting a potential upside of 110.08%. As a group, “Analytical instruments” companies have a potential upside of 10.89%. Given IsoPlexis’ higher probable upside, analysts plainly believe IsoPlexis is more favorable than its peers.
Profitability
This table compares IsoPlexis and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IsoPlexis | -632.41% | -127.86% | -71.41% |
| IsoPlexis Competitors | -273.31% | 238.74% | -17.34% |
Volatility & Risk
IsoPlexis has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, IsoPlexis’ peers have a beta of 1.04, meaning that their average share price is 4% more volatile than the S&P 500.
Institutional & Insider Ownership
44.9% of IsoPlexis shares are held by institutional investors. Comparatively, 55.7% of shares of all “Analytical instruments” companies are held by institutional investors. 6.4% of IsoPlexis shares are held by company insiders. Comparatively, 17.4% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
IsoPlexis peers beat IsoPlexis on 10 of the 13 factors compared.
IsoPlexis Company Profile
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.
